I will give a Cheat sheet mTNBC Survival & Trea

I will give a Cheat sheet

mTNBC Survival & Treatment Cheat Sheet
???? What is mTNBC?

Triple-negative breast cancer that has spread (metastatic)

Lacks estrogen, progesterone, HER2 receptors → few targeted treatments

Fast-growing, hard to treat, especially after first-line therapy fails

???? Median Overall Survival (mOS) benchmarks

1st-line (chemo ± immunotherapy) → 12–17 months

2nd-line (chemo, ADCs like Trodelvy) → 6–9 months

3rd-line+ (mostly chemo) → ~6–6.5 months

???? Approved Late-Line Treatments

Treatment mOS Improvement Notes
Trodelvy (sacituzumab govitecan) ~12 months vs. ~6.7 (chemo) Late-line game-changer, ADC technology
Pembrolizumab + chemo (PD-L1+) ~23 months vs. ~16 (chemo) Only works if PD-L1 positive, 1st line
Atezolizumab + nab-paclitaxel ~25 months (PD-L1+ 1st line) Withdrawn in U.S., confirmatory failure

⚡ Leronlimab (Investigational, CytoDyn)

Small late-line trial → 4 of 28 patients alive after ~36 months

Chemo-refractory, very advanced patients

Survival durability far exceeds expected median (~6 months)

Mechanism: CCR5 blockade → may inhibit tumor metastasis, immune evasion

???? Other Promising Agents (early stage)

Datopotamab deruxtecan (Dato-DXd) → ADC, promising early data

Enfortumab vedotin → ADC, in exploration

Ipatasertib (AKT inhibitor) → mixed results, still under study

CAR-T, bispecific antibodies → very early, experimental

???? Why is leronlimab exciting?

Potential for paradigm-shifting late-line survival

Unique immune and anti-metastatic mechanism

Needs larger confirmatory trials to validate small-study signals

???? Takeaway
If leronlimab’s durability holds up, it could join or exceed Trodelvy’s impact in mTNBC, providing hope in one of the toughest-to-treat cancers.